Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Carlos H. Arteaga"'
Autor:
Nurullah Akkoç, Carlos H. Arteaga, Simone E. Auteri, Marissa Betts, Kyle Fahrbach, Mindy Kim, Sandeep Kiri, Binod Neupane, Karl Gaffney, Philip J. Mease
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 2, Pp 307-327 (2023)
Abstract Introduction Biologic disease-modifying anti-rheumatic drugs (bDMARDs), including certolizumab pegol (CZP), are effective treatment options for the management of non-radiographic spondyloarthritis (nr-axSpA). In the absence of head-to-head c
Externí odkaz:
https://doaj.org/article/2ac7e2053157492b9c3f150d1bdbe02c
Autor:
Renée E. Michels, Carlos H. Arteaga, Michel L. Peters, Ellen Kapiteijn, Carla M. L. Van Herpen, Marieke Krol
Publikováno v:
Applied Health Economics and Health Policy, 20, 717-729
Applied Health Economics and Health Policy, 20(5), 717-729. SPRINGER INT PUBL AG
Applied Health Economics and Health Policy, 20, 5, pp. 717-729
Applied Health Economics and Health Policy, 20(5), 717-729. SPRINGER INT PUBL AG
Applied Health Economics and Health Policy, 20, 5, pp. 717-729
Contains fulltext : 283346.pdf (Publisher’s version ) (Open Access) BACKGROUND: Larotrectinib is the first tumour-agnostic therapy that has been approved by the European Medicines Agency. Tumour-agnostic therapies are indicated for a multitude of t